CN100567325C

CN100567325C - Vegf receptor fusion rotein and the application in the medicine of preparation treatment disease of eye thereof

Info

Publication number: CN100567325C
Application number: CNB2008101608428A
Authority: CN
Inventors: 俞德超
Original assignee: Chengdu Kanghong Biotechnologies Co Ltd
Current assignee: Chengdu Kanghong Biotechnologies Co Ltd
Priority date: 2006-03-31
Filing date: 2006-03-31
Publication date: 2009-12-09
Anticipated expiration: 2026-03-31
Also published as: CN101397343A

Abstract

The present invention relates to two vegf receptor fusion roteins, its preparation method and the application in the treatment disease of eye thereof, described disease of eye comprises age-related macular degeneration, diabetic retinopathy, the operation retina transplantation is failed as the laser photocoagulation body in diabetes xanthelasma body of gland and the treatment that is caused by the new vessel growth.

Description

Vegf receptor fusion rotein and the application in the medicine of preparation treatment disease of eye thereof

The application is to be on March 31st, 2006 applying date, and application number is 200610066257.2, and denomination of invention is divided an application for the Chinese invention patent application of " the vegf receptor fusion rotein is in the application of treatment in the disease of eye ".

Technical field:

The present invention relates to the application of vegf receptor fusion rotein in the various ophthalmic diseasess that treatment causes because of the growth of new vessel.

Background technology:

Retinal blood guard system and choroid (chorodial) vascular system is to form amphiblestroid important component part.Wound or disease and the vascular wall structure that causes or the abnormal change of function are the major causes that causes visual deterioration or forfeiture.For example, diabetic retinopathy (diabetic retinopathy) is owing to diabetes cause the retinal vessel hyperplasia, and then causes retina shedding.It is the major cause that causes visual loss.In injured back of eyes or postoperative recovery process, also may cause the growth of new vessel in the retina.This class retinal vessel hyperplasia also is to cause visual deterioration or the blind major reason (Nature 438:932-938,2005) of eyes.

Relevant macular degeneration (AMD) of age is a kind of cell or tissue degeneration and blood vessel hyperplasia and disease of causing by the foveal region of retina district.Can divide dryness and moist two kinds.Wherein moist AMD is the most common form that choroidal neovascularization forms, and it also is the major cause that causes that eyes are blind.

Vascular endothelial growth factor (VEGF) is the protein (Am.J.Pathol.167:1451-1459,2005) of species specificity regulation and control new vessel growth.VEGF stimulating endothelial cell division and proliferation, and then promote the new vessel growth, to provide nutrition and oxygen to histocyte.In case the photosensory cell that much studies show that eye retina is owing to under-nutrition begins atrophy (being called " ischemia atrophy "), VEGF just begins to raise in intraretinal concentration, thereby promotes the new vessel growth.This process is called " formation of new vessel " (angiogenesis).Within the eye, neonatal blood vessels is different with normal blood vessels on form, and tube chamber is irregular, and tube wall mostly is seepage.The paraplasm of the blood vessel of this high-permeability or seepage often causes producing on the retina scar, thereby and further can come off and have influence on eyesight.

In many tela chorioideas that studies show that moist patient AMD high-caliber vegf expression (Invest.Opthal.Vis.Sci 37:855-868,1996 are arranged; Microvascular Res.64:162-169,2002).Because the dependency between vegf expression level and the moist AMD, VEGF can be used as a biochemical indicator (Br.J.Opthalmol.88:809-815,2004) of diagnosing AMD.

Some VEGF inhibitor can blocking VEGF and endotheliocyte on interaction between the vegf receptor (flt-1, KDR etc.), thereby stop information conduction by the VEGF mediation, the growth of the new vessel that inhibition is caused by the VEGF high expression level is to reach prevention and to stop hemorrhage purpose on the retina.This class VEGF inhibitor comprises Macugen (pegaptanib sodium), Lucentis, VEGF-Trap, Avastin (bevacizumab) and AdPEDF etc.Wherein Macugen and Avastin are by American National Food and Drug Administration (FDA) approval listing.

Summary of the invention:

The invention provides the fusion rotein that a class suppresses VEGF, can be used for treating the various ophthalmic diseasess that the growth owing to new vessel causes.Described disease includes, but is not limited to described disease of eye and comprises age-related macular degeneration, diabetic retinopathy, and the operation retina transplantation is failed as the laser photocoagulation body in diabetes xanthelasma body of gland and the treatment that is caused by the new vessel growth.In the present invention, described fusion rotein is meant macromolecular cpd, particularly the recombination fusion protein of vegf receptor.More specifically, VEGF inhibitor of the present invention is the FP that describes in the Chinese patent application " fused protein of angiogenesis inhibiting and uses thereof " (application number CN200510073595.4) ₁, FP ₂, FP ₃, FP ₄, FP ₅, FP ₆With FP provided by the invention ₇And FP ₈In any.FP wherein ₁, FP ₂, FP ₃, FP ₄, FP ₅, FP ₆The fusion rotein aminoacid sequence in above-mentioned patent specification, FP ₇And FP ₈Sequence 1 and the sequence 2 of aminoacid sequence in sequence table of the present invention.

Vegf receptor fusion rotein of the present invention can be by the preparation of the method in the above-mentioned patent specification, wherein FP ₁, FP ₂, FP ₃, FP ₄, FP ₅, FP ₆Be known substance, FP ₇And FP ₈Be novel substance, for novel substance, the invention provides its preferred manufacturing procedure embodiment, its preparation principle is identical with above-mentioned patent specification.

The goods that the present invention makes through recombinant technology reach medicinal purity through purifying, needs according to preparation are prepared into pharmaceutical preparation with it more then, these preparations should be particularly suitable for intravenous administration, intravitreal injection administration, abdominal injection, subcutaneous injection, local eye drops, its preparation technology can adopt the routine fashion of pharmaceutical preparation to finish, preferably pharmaceutical solutions or dry powder formulations, as dry powder formulations, during use dry powder dissolving being made becomes solution.Fusion protein formulations of the present invention, can add the medicine acceptable carrier when needing, described carrier can be any pharmaceutical carrier that is fit to dosage form of the present invention, preferably be selected from: sodium phosphate (sodium phosphate), sodium succinate (sodium succinate), Histidine (histidine), N.F,USP MANNITOL (mannitol), trehalose (trehalose dihydrate), polysorbate (polysorbate20), sodium-chlor (sodium chloride), sucrose (sucrose), Tutofusin tris (trometamol) or lactose, above-mentioned preparation damping fluid (formulation buffer), should contain pH buffering system such as phosphoric acid salt (phosphate), Citrate trianion (citrate), acetate (acetate), succinate (succinate), Tutofusin tris (trometamol, have another name called Tris) or Histidine (histidine) etc. in a kind of, the scope of pH is 3 to 9; Can contain osmotic pressure regulator such as sodium-chlor (sodium chloride), glucose (dextrose) etc.; Can contain stablizer such as amino acid (amino acids), glycerine (glycerol), cyclodextrin (cyclodextrin), sucrose (sucrose), trehalose (trehalose dihydrate) etc.; Sanitas such as thiophene mercury be can contain and (thimerosal), sodium bisulfite (sodium bisulfite), phenylethyl alcohol (benzylalcohol) etc. spread.For freeze-dried preparation, can contain vehicle such as N.F,USP MANNITOL (mannitol) etc.; For pharmaceutical solutions, can contain tensio-active agent such as polysorbate (polysorbate 20 or 80), sodium laurylsulfonate (SDS) etc.The concentration range of fusion rotein is at 0.01mg/ml to 1000mg/ml.Its consumption is decided according to clinical needs.Also ancillary components such as sanitas, stablizer, solubility promoter can be added as required in the preparation in addition, the ancillary component of any suitable pharmaceutics routine can be selected from.Solvent is selected water or other isotonic solution, buffered soln etc.

Among the present invention, also introduced the medication of VEGF inhibitor simultaneously.These inhibitor can give patient by multiple different route of administration, and comprising (but being not limited to) intravenously administrable, intravitreal injection also can be by giving patient to reach the purpose of treatment eye illness in the mode of putting drops in one's eyes under certain formulation.

The unexpected VEGF inhibitor of fusion rotein form of the present invention of finding of the present invention has good curing eye diseases effect than prior art, and good stability, safe, side effect is little, effect is good, the present invention by experiment digital proof beneficial effect of the present invention, concrete data are seen embodiment.

Description of drawings:

Fig. 1: the structural representation of 8 kinds of fusion roteins of the present invention

Fig. 2: the comparison of fusion rotein and VEGF bonded avidity

Fig. 3: the influence that the fusion rotein new vessel that atrophy causes to retinal ischemia forms

Fig. 4: fusion rotein is to the influence of choroidal neovascularization growth

Embodiment:

Further specify the present invention by the following examples, but not as limitation of the present invention.

Embodiment 1, FP ₇Structure

Fusion protein F P7 be by primer flt-1D2 (F), flt-1D2 (R), KDR D3 (F) and KDRD3-4 (R) (seeing application for patent, application number CN200510073595.4) from the HUVEC cell extraction to the mRNA flt-1 and the reorganization of KDR gene fragment that are amplified to as template synthetic cDNA form.Concrete condition is 95 ° of sex change, 30 minutes, anneals 56 °, 45 seconds, extends under 72 °, 2 minutes the condition, carries out pcr amplification, and 30 circulations obtain the PCR product in flt-1 and KDR 1gG spline structure territory.With TA cloning test kit, in the PCR2.1 plasmid, and transfection E.coli chooses white colony the PCR product cloning, adds the LB substratum, overnight incubation.Extract behind the plasmid enzyme evaluation of cutting and check order with the Qiangen plasmid extraction kit.Adopt splicing PCR (Sewing PCR) method, the Yeast Nucleic Acid of the local sequence of flt-1 fragment, KDR fragment and IgG hinge area is connected together.Design EcoR1 restriction enzyme site in the primer of two ends.The PCR end product through Qiangen purification kit purifying DNA fragment, and inserts the pcDNA3.1 plasmid after cutting with the EcoR1 enzyme.Recombinant plasmid transfection E.coli chooses positive bacterium colony, adds the LB substratum, overnight incubation.Enzyme was cut after the Qiangen plasmid extracted plasmid, and order-checking is identified.The plasmid that the has obtained confirmation clone that transfection CHO cell must stably express fusion protein F P7 again.FP ₇Concrete nucleotide sequence see sequence table 3.Remain with the partial sequence of hinge area (hinge) at this fusion rotein C-terminal.

Embodiment 2, FP ₈Structure

Fusion protein F P8 is to be that template directly forms with pcr amplification with FP7, and the PCR the primer is flt-1D2 (F) and KDR D3-hing (R).The latter's sequence is: 5 '-aggtgctgggcacagtgggcatgtgtgagttttgtctttttcatggaccctgacaa atg.It comprises the partial nucleotide sequence of complementary sequence and human IgG Fc hinge region mutually with KDR the 3rd immunoglobulin-like district.The method of pcr amplification and gene clone is identical with example 1.Insert the Pc DNA3.1 plasmid transfection Chinese hamster ovary celI of FP8 the most at last, and obtained stable cell line, be used for protein expression.The aminoacid sequence of FP8 is seen sequence table 2, and nucleotide sequence is seen sequence table 4.

The experiment of embodiment 3 fusion roteins and VEGF binding affinity

The present invention determines the ability of various fusion roteins in conjunction with VEGF with the amount of measuring VEGF.In this test, a certain amount of VEGF (10PM) is added in the test tube, then the diluted various fusion roteins that contain different amounts are added in the test tube that contains VEGF, after mixing, in 37 ° incubator, preserved one hour.After one hour, free VEGF is by R﹠amp in the test tube; (the R﹠amp of d system company; The test kit of the detection VEGF amount that D systems) provides---VEGF detection kit (VEGF assay Kit) mensuration.The result who is measured to is through the processing of software and obtain result as Fig. 2, and Fig. 2 shows, FP ₁, FP ₃And FP ₇Can both combine with VEGF is affine effectively, it can be by IC in conjunction with affinity ₅₀Expression is respectively 11.2PM, 4.3PM and 4.1PM.This experiment showed, FP ₃And FP ₇Similar in external binding ability to VEGF, and the both is higher than FP ₁

But this test-results further illustrates the aminoacid sequence promote fusion albumen in the 4th immunoglobulin-like zone of KDR to the binding ability of VEGF.

Embodiment 4 fusion roteins stop the experimental result that forms of the new vessel that is caused by the retinal ischemia atrophy

Seven days young mouse of birth is placed in the incubator that contains high keto sectional pressure (75% ± 2%), and controlled temperature is 23 ℃ ± 2 ℃ natural illumination.After cultivating several days with this understanding, foveal region of retina will not have angiogenesis to be taken place, and after five days, young mouse is put back in the incubator of normal oxygen partial pressure.Because indoor relatively low oxygen partial pressure concentration and the retina of young mouse is produced hypoxia condition, be similar to diabetic retinopathy and other are because new vesseles reaction of ischemia atrophy retinopathy thereby stimulate to produce.

Utilize this model, can be to three kinds of fusion rotein (FP ₁, FP ₃And FP ₇) make assessment in the effect aspect the relevant new vessel generation of ischemia atrophy retinopathy.

Young mouse is placed in the incubator of high keto sectional pressure, brings back in the indoor incubator of normal oxygen partial pressure after five days.The children mouse is divided into five groups, 10 every group, after one day with the amount of 30mg/kg with fusion rotein through abdominal injection children mouse, injection in per two days is once injected altogether 4 times.The young mouse of control group is then contained the Fc albumen of same amount by injection.The treatment phase is got 6 of mouse from each group after finishing, injection of heart fluorescein FAM, and after 10 minutes, the retina of young mouse is won the generation situation that is used for analyzing new vessel.During operation retina is set level, observed new vessel and fluorescence leakage situation under fluorescent microscope, each organizes the eyes paraffin embedding of all the other four mouse, section back H﹠amp; E dyeing.Mirror is the number of counting vascular endothelial cell nuclear down, thereby judges the influence (Investigative Ophthalomogy visual science 43,1994-2000,2002) of fusion rotein to the new vessel growth.The result as shown in Figure 3.The young mouse retina of accepting the Fc protein injection all shows serious pathology.In retinal surface, can be observed a large amount of rambling blood vessels on the arteries and veins film.On its retina of young mouse of handling through fusion rotein, then there is not tangible angiogenic growth (as Fig. 3). FP wherein ₃The most effective, FP ₇Also more effective, but its effect is similar to FP ₁, its major cause may be to influence its stability in vivo because of disappearance Fc fragment.FP ₁With FP ₇Effect similar.

Simultaneously, we also tested with these fusion roteins by under the situation of glass vivo medicine-feeding to the influence of new vessel.Same animal model is adopted in test, after one day, carries out intravitreal injection with the amount of 0.5 milligram of every eye in animal gets back to the incubator of normal oxygen partial pressure, and every animal is only accepted seance.Administration the 7th day afterwards, the retina of animal is collected as stated above and is handled.Fusion rotein to the influence of new vessel as shown in Figure 3.The result shows that through intravitreal injection, these fusion roteins have significant inhibitory effect to the growth of new vessel.The action effect of intravitreal injection is better than abdominal injection.Simultaneously, by this group experiment, we observe FP ₇Effect be similar to FP ₃The both is better than FP ₁In this test, owing to be intravitreal injection, FP7 does not need to circulate through the body inner blood.Therefore, the material that its blood internal stability is lower can not influence its curative effect.

Embodiment 5 fusion roteins are to the influence of laser induced choroidal neovascularization growth

According to the documents and materials of delivering (American Journal Pathology 153,1641-1646,1998), we utilize laser to set up on the eyes of rat can bring out the AMD model that the eyeground choroidal neovascularization generates.About 150 rats are divided into four groups, and 10 rats of control group are accepted Fc albumen (20mg/kg) by subcutaneous injection, and per 10 rats of handling are the FP by subcutaneous injection 20mg/kg respectively ₁, FP ₃And FP ₇Accept injection, the 3rd, 6,9 and 12 day after laser treatment the day before yesterday and laser treatment respectively altogether 5 times.After laser treatment the 15th day, rat was accepted the fluorescently-labeled dextran of 50mg by intravenous injection, then through anaesthetic treatment, eyes was extractd, and peeled off choroid as early as possible, cutd open into flats or freezing embedding and did section and be used to analyze CNV pathology situation.Result such as Fig. 4 show that it is little all to compare photograph (Fc) through the CNV area of fusion rotein processing mouse, wherein FP ₃Effect be better than FP ₁And FP ₇FP ₇With FP ₁Inhibition CNV generation aspect effect suitable.

The application of embodiment 6 fusion roteins in the treatment eye illness

These fusion roteins can be by suitable mode, as intravitreal injection or intravenously administrable, can be used for treating and the relevant a series of ophthalmic diseasess of pathology new vessel growth, comprising age-related macular degeneration (AMD), diabetic retinopathy (diabetic retinopathy), diabetic macular edema (diabeticmacular edema) and retinal vessel occlusion (central retinal vein occlusion).Simultaneously these fusion roteins also can be used in combination together with the other treatment method, as and photosensitive drug (photocoagulation) or be used in combination with laser therapy, to be reduced in the treatment failure probability that causes by the new vessel growth after the laser treatment.These fusion roteins can also be used in combination with operation.As after retina transplantation, make the operative failure of retina transplantation owing to the growth of new vessel.If in operation, patient accepts the treatment of these fusion roteins, just can improve the success ratio of retina transplantation.Patient AMD sets up basic reference line after by normal eye examination, then the method by intravitreal injection with fusion rotein (as FP ₃Or FP ₇) inject in the body.Patient will arrive hospital and accept O﹠E after treatment, to write down the influence of these fusion roteins to AMD.Generally after receiving treatment, checked respectively once in the 1st, 2,6,14,30 and 90 day.Simultaneously, patient may need to accept repeatedly treatment, can be to inject once in per two to eight weeks.The amount of per injection is in every eyes 10 microgram to 5 nanogram ranges.

The preparation of embodiment 7 FP3 fusion rotein freeze-dried preparation

Prepare preparation damping fluid (formulation buffer) earlier, after qualified stoste (drug substance) is thawed, be diluted to required protein concentration with the preparation damping fluid.After carrying out filtration sterilization, with pipettor/dispenser on request the loading amount branch be filled to clean cillin bottle (specification: 0.5ml/2ml), add clean butyl rubber bung (half tamponade) toward bottleneck.Put into freeze drier, configure suitable freeze-drying curve (comprising the isoparametric setting of time, temperature, vacuum tightness in pre-freeze, freezing, each stage that vacuumizes, heats up), carry out freeze-drying.After freeze-drying process finishes, compress plug, take out cillin bottle, on plug, add aluminium-plastic cap, cover device and roll tightly with rolling.Label on cillin bottle, the carton of packing into is deposited in suitable temperature.

The preparation of embodiment 8 FP3 fusion rotein pharmaceutical solutionses

Prepare preparation damping fluid (formulation buffer) earlier, after qualified stoste (drug substance) is thawed, be diluted to required protein concentration with the preparation damping fluid.After carrying out filtration sterilization, with pipettor/dispenser on request the loading amount branch be filled to clean cillin bottle (specification: 5ml/20ml), add clean butyl rubber bung, jam-pack toward bottleneck.Add aluminium-plastic cap beyond the Great Wall at isoprene-isobutylene rubber, cover device and roll tightly with rolling.Label on cillin bottle, the carton of packing into is deposited in suitable temperature.

The preparation of embodiment 9 FP3 fusion rotein ophthalmic preparation

Prepare the preparation damping fluid earlier, after qualified stoste (drug substance) is thawed, be diluted to required protein concentration with the preparation damping fluid.After carrying out filtration sterilization, with pipettor on request loading amount (≤200 μ l) divide and to be filled to clean cillin bottle (specification: 0.5ml), or be pumped to glass syringe (specification: 1ml is with grey rubber piston, No. 27 syringe needles) and require loading amount (≤100 μ l).For cillin bottle, add clean butyl rubber bung at the bottleneck end, jam-pack adds aluminium-plastic cap beyond the Great Wall at isoprene-isobutylene rubber, covers device and rolls tightly with rolling, and labels on cillin bottle; For syringe, the place installs rubber plug additional at piston, installs grey rubber cover on syringe needle additional, installs additional to mould cover firmly outside rubber cover again, with aluminium envelope (label out of the press) encapsulation (being furnished with threaded plastic piston bar, white flanged ends in addition) with different aluminium envelope encapsulation.The carton of packing into is deposited in suitable temperature.

The preparation of embodiment 10 FP1 fusion rotein ophthalmic preparation, the preparation method is with embodiment 9

The preparation of embodiment 11 FP2 fusion rotein ophthalmic preparation, the preparation method is with embodiment 9

The preparation of embodiment 12 FP4 fusion rotein ophthalmic preparation, the preparation method is with embodiment 9

The preparation of embodiment 13 FP5 fusion rotein ophthalmic preparation, the preparation method is with embodiment 9

The preparation of embodiment 14 FP6 fusion rotein ophthalmic preparation, the preparation method is with embodiment 9

The preparation of embodiment 15 FP7 fusion rotein ophthalmic preparation, the preparation method is with embodiment 9

Sequence table

＜110〉Kanghong Biotech Co., Ltd., Chengdu

＜120〉application of vegf receptor fusion rotein in the medicine of preparation treatment disease of eye

<160>4

<210>1

<211>308

<212>PRT

＜213〉artificial sequence

<400>1

GlyArgProPheValGluMetTyrSerGluIleProGluIleIle?15

HisMetThrGluGlyArgGluLeuValIleProCysArgValThr?30

SerProAsnIleThrValThrLeuLysLysPheProLeuAspThr?45

LeuIleProAspGlyLysArgIleIleTrpAspSerArgLysGly?60

PheIleIleSerAsnAlaThrTyrLysGluIleGlyLeuLeuThr?75

CysGluAlaThrValAsnGlyHisLeuTyrLysThrAsnTyrLeu?90

ThrHisArgGlnThrAsnThrIleIleAspValValLeuSerPro?105

SerHisGlyIleGluLeuSerValGlyGluLysLeuValLeuAsn?120

CysThrAlaArgThrGluLeuAsnValGlyIleAspPheAsnTrp?135

GluTyrProSerSerLysHisGlnHisLysLysLeuValAsnArg?150

AspLeuLysThrGlnSerGlySerGluMetLysLysPheLeuSer?165

ThrLeuThrIleAspGlyValThrArgSerAspGlnGlyLeuTyr?180

ThrCysAlaAlaSerSerGlyLeuMetThrLysLysAsnSerThr?195

PheValArgValHisGluLysProPheValAlaPheGlySerGly?210

MetGluSerLeuValGluAlaThrValGlyGluArgValArgIle?225

ProAlaLysTyrLeuGlyTyrProProProGluIleLysTrpTyr?240

LysAsnGlyIleProLeuGluSerAsnHisThrIleLysAlaGly?255

HisValLeuThrIleMetGluValSerGluArgAspThrGlyAsn?270

TyrThrValIleLeuThrAsnProIleSerLysGluLysGlnSer?285

HisValValSerLeuValValTyrValProProAspLysThrHis?300

ThrCysProLeuCysProAlaPro?308

<210>2

<211>214

<212>PRT

＜213〉artificial sequence

<400>2

GlyArgProPheValGluMetTyrSerGluIleProGluIleIle?15

HisMetThrGluGlyArgGluLeuValIleProCysArgValThr?30

SerProAsnIleThrValThrLeuLysLysPheProLeuAspThr?45

LeuIleProAspGlyLysArgIleIleTrpAspSerArgLysGly?60

PheIleIleSerAsnAlaThrTyrLysGluIleGlyLeuLeuThr?75

CysGluAlaThrValAsnGlyHisLeuTyrLysThrAsnTyrLeu?90

ThrHisArgGlnThrAsnThrIleIleAspValValLeuSerPro?105

SerHisGlyIleGluLeuSerValGlyGluLysLeuValLeuAsn?120

CysThrAlaArgThrGluLeuAsnValGlyIleAspPheAsnTrp?135

GluTyrProSerSerLysHisGlnHisLysLysLeuValAsnArg?150

AspLeuLysThrGlnSerGlySerGluMetLysLysPheLeuSer?165

ThrLeuThrIleAspGlyValThrArgSerAspGlnGlyLeuTyr?180

ThrCysAlaAlaSerSerGlyLeuMetThrLysLysAsnSerThr?195

PheValArgValHisGluLysAspLysThrHisThrCysProLeu?210

CysProAlaPro?214

<210>3

<211>924

<212>DNA

＜213〉artificial sequence

<400>3

ggtagacctt?tcgtagagat?gtacagtgaa?atccccgaaa?ttatacacat?gactgaagga?60

agggagctcg?tcattccctg?ccgggttacg?tcacctaaca?tcactgttac?tttaaaaaag?120

tttccacttg?acactttgat?ccctgatgga?aaacgcataa?tctgggacag?tagaaagggc?180

ttcatcatat?caaatgcaac?gtacaaagaa?atagggcttc?tgacctgtga?agcaacagtc?240

aatgggcatt?tgtataagac?aaactatctc?acacatcgac?aaaccaatac?aatcatagat?300

gtggttctga?gtccgtctca?tggaattgaa?ctatctgttg?gagaaaagct?tgtcttaaat?360

tgtacagcaa?gaactgaact?aaatgtgggg?attgacttca?actgggaata?cccttcttcg?420

aagcatcagc?ataagaaact?tgtaaaccga?gacctaaaaa?cccagtctgg?gagtgagatg?480

aagaaatttt?tgagcacctt?aactatagat?ggtgtaaccc?ggagtgacca?aggattgtac?540

acctgtgcag?catccagtgg?gctgatgacc?aagaagaaca?gcacatttgt?cagggtccat?600

gaaaaacctt?ttgttgcttt?tggaagtggc?atggaatctc?tggtggaagc?cacggtgggg?660

gagcgtgtca?gaatccctgc?gaagtacctt?ggttacccac?ccccagaaat?aaaatggtat?720

aaaaatggaa?taccccttga?gtccaatcac?acaattaaag?cggggcatgt?actgacgatt?780

atggaagtga?gtgaaagaga?cacaggaaat?tacactgtca?tccttaccaa?tcccatttca?840

aaggagaagc?agagccatgt?ggtctctctg?gttgtgtatg?tcccaccgga?caaaactcac?900

acatgc?ccac?tgtgcccagc?acct?924

<210>4

<211>642

<212>DNA

＜213〉artificial sequence

<400>4

ggtagacctt?tcgtagagat?gtacagtgaa?atccccgaaa?ttatacacat?gactgaagga?60

agggagctcg?tcattccctg?ccgggttacg?tcacctaaca?tcactgttac?tttaaaaaag?120

tttccacttg?acactttgat?ccctgatgga?aaacgcataa?tctgggacag?tagaaagggc?180

ttcatcatat?caaatgcaac?gtacaaagaa?atagggcttc?tgacctgtga?agcaacagtc?240

aatgggcatt?tgtataagac?aaactatctc?acacatcgac?aaaccaatac?aatcatagat?300

gtggttctga?gtccgtctca?tggaattgaa?ctatctgttg?gagaaaagct?tgtcttaaat?360

tgtacagcaa?gaactgaact?aaatgtgggg?attgacttca?actgggaata?cccttcttcg?420

aagcatcagc?ataagaaact?tgtaaaccga?gacctaaaaa?cccagtctgg?gagtgagatg?480

aagaaatttt?tgagcacctt?aactatagat?ggtgtaaccc?ggagtgacca?aggattgtac?540

acctgtgcag?catccagtgg?gctgatgacc?aagaagaaca?gcacatttgt?cagggtccat?600

gaaaaagaca?aaactcacaca?tgcccactgt?gcccagcac?ct?642

Claims

1. the receptor fusion protein FP7 of vascular endothelial growth factor VEGF, its aminoacid sequence is shown in the sequence in the sequence table 1.

2. the gene of coding vascular endothelial growth factor vegf receptor fusion protein F P7, its nucleotide sequence is shown in the sequence in the sequence table 3.

3. the expression carrier that contains vascular endothelial growth factor vegf receptor fusion protein F P7 as claimed in claim 2.

4. a method for preparing the receptor fusion protein FP7 of VEGF as claimed in claim 1 comprises the steps: to utilize gene recombination technology to make up the carrier that contains antigen-4 fusion protein gene, with this carrier quiding gene engineering cell, expresses this fusion rotein.

5. pharmaceutical composition comprises acceptable carrier on the receptor fusion protein FP7 of the described VEGF of claim 1 that treats significant quantity and optional one or more pharmacology.

6. pharmaceutical composition according to claim 5, described carrier are selected from one or more in damping fluid between the PH3-9, stablizer, sanitas, solubility promoter, vehicle, the osmotic pressure regulator.

7. pharmaceutical composition according to claim 6, described carrier are selected from one or more in phosphate buffered saline buffer, succinate damping fluid, histidine buffering liquid, N.F,USP MANNITOL, trehalose, polysorbate, sodium-chlor, sucrose, Tutofusin tris or the lactose.

8. according to each described pharmaceutical composition of claim 5-7, it is prepared into the pharmaceutical preparation that is suitable for using, and described preparation is selected from freeze-dried preparation or pharmaceutical solutions.

9. pharmaceutical composition according to claim 8, the administering mode of its preparation are selected from intravitreal injection, intravenous administration, abdominal injection, subcutaneous injection or with the administration of collyrium eye drip mode.

10. the described fusion protein F P7 of claim 1, the described gene of claim 2 or each described pharmaceutical composition of claim 5-9 application in the medicine of the preparation treatment ophthalmic diseases relevant with the new vessel growth, the wherein said ophthalmic diseases relevant with the new vessel growth is selected from the age related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, the treatment failure that causes by the new vessel growth.

11. application according to claim 10, the described treatment failure that is caused by the new vessel growth is selected from the laser photocoagulation body, the operation retina transplantation.